[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 53 of about 53
1. Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K, Saitoh A, Oouchi A, Fukuda S, Himi T: A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer; 2002 Apr 15;94(8):2217-23
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma.
  • BACKGROUND: A prospective, randomized study was performed to determine the efficacy of neoadjuvant chemotherapy over radiotherapy alone in patients with locally advanced nasopharyngeal carcinoma.
  • Patients with locoregional carcinoma of the nasopharynx were randomized to receive two courses of chemotherapy, consisting of cisplatin and 5-fluorouracil (CDDP-5FU), that were administered before radiation therapy (CT arm) or radiotherapy alone.
  • The patients who received neoadjuvant chemotherapy were treated with radiation therapy, which was scheduled to commence 2 weeks after the second course chemotherapy.
  • However, metastasis free survival favored the CT arm, although this difference was not significant.
  • The results also demonstrated that most patients in the CT arm who experienced recurrent disease developed locoregional recurrences before distant metastases, suggesting that improvements in locoregional control may lead to improved disease free survival.
  • CONCLUSIONS: The use of CDDP-5FU chemotherapy prior to radiotherapy in patients with nasopharyngeal carcinoma did not result in a significant improvement in disease free survival or overall survival.
  • However, there was a positive tendency in favor of the CT arm for distant metastasis free survival, although there was no improvement in the locoregional recurrence free survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12001120.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Lin JC, Jan JS, Hsu CY, Jiang RS, Wang WY: Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates. Br J Cancer; 2003 Jan 27;88(2):187-94
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates.
  • Nasopharyngeal carcinoma (NPC) is a radiosensitive and chemosensitive tumour.
  • The aim of this prospective study is to evaluate the toxicity and efficacy of an outpatient weekly neoadjuvant chemotherapy (NeoCT) plus radiotherapy for advanced NPC.
  • (2) supraclavicular node metastasis;.
  • (3) skull base destruction/intracranial invasion plus multiple nodes metastasis;.
  • (4) multiple neck nodes metastasis with one of nodal size >4 cm; or (5) elevated serum LDH level.
  • Local radiotherapy > or =70 Gy by conventional fractionation was delivered within 1 week after NeoCT.
  • After a median follow-up time of 24 months, one persistent disease and 18 relapses were noted.
  • The 2-year nasopharynx disease-free, neck disease-free, distant disease-free, overall, and progression-free survival rates are 98.9, 95.9, 80.0, 92.1, and 77.5%, respectively.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Neoplasm Staging. Outpatients. Patient Compliance. Prospective Studies. Survival Rate. Treatment Failure

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):901-5 [10571196.001]
  • [Cites] Radiology. 1999 May;211(2):513-8 [10228536.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1323-30 [11121629.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1105-10 [11181675.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1350-7 [11230478.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23):4305-13 [11731513.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1238-44 [11955734.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2038-44 [11956263.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2217-23 [12001120.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1789-93 [2412999.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1401-10 [3047335.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):261-70 [1587745.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):569-77 [7558945.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):463-9 [8655368.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1127-36 [8985035.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1279-86 [9083147.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):985-96 [9169804.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2270-83 [9840526.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):261-71 [10030248.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1277-9 [11121623.001]
  • (PMID = 12610501.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 22
  • [Other-IDs] NLM/ PMC2377053
  •  go-up   go-down


3. Boussen H, Bouaouina N, Daldoul O, Benna F, Gritli S, Ladgham A: [Update on medical therapies of nasopharyngeal carcinomas]. Bull Cancer; 2010 Apr;97(4):417-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Update on medical therapies of nasopharyngeal carcinomas].
  • [Transliterated title] Actualités des traitements médicaux des cancers du nasopharynx.
  • Nasopharyngeal carcinomas (NPC) are predominantly of undifferentiated type (UCNT or undifferentiated carcinoma of nasopharyngeal type), rare (<1/100,000) and sporadic in occidental countries, but endemic in the Mediterranean area of intermediate incidence (2 to 10/100,000) and highly frequent (>10/100,000) in South East Asia.
  • NPC staging is based on TNM UICC 2002 that has a prognostic and therapeutic orientation impact.
  • Irradiation of the primitive tumor and its extensions remains the standard loco-regional treatment.
  • The recent introduction of primary and concomitant chemotherapy leads to an improvement in terms of overall and disease-free survival, specially for for high-risk-patients (T3-4 and N2-3 disease).
  • Prognosis remain linked to T, N, histologic type and quality of response to chemotherapy and radiotherapy.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Age of Onset. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy / methods. Disease-Free Survival. Dose Fractionation. Humans. Infant. Infant, Newborn. Lymphatic Metastasis. Neoplasm Staging. Treatment Outcome. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20385516.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Pérez Plasencia D, Gómez González JL, Santa Cruz Ruiz S, Muñoz Herrera A, Mateos Pérez MM, Flores T, Pardal JL: [Clinical descriptive study of 40 patients with carcinoma of the nasopharynx in advanced stage in an area of low epidemiological risk]. Acta Otorrinolaringol Esp; 2002 Aug-Sep;53(7):473-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical descriptive study of 40 patients with carcinoma of the nasopharynx in advanced stage in an area of low epidemiological risk].
  • [Transliterated title] Estudio clínico descriptivo de 40 pacientes con carcinoma de nasofaringe en estadio avanzado en un área de bajo riesgo epidemiológico.
  • The nasopharyngeal carcinoma in Spain, low risk geographical area, is a rare tumor.
  • We have selected among all the patients diagnosed of nasopharyngeal carcinoma a big group who, have been treated with induction chemotherapy followed by radiotherapy with or without surgery, they presented very complete clinical histories in the Departments of E.N.T., Oncology and Radiotherapy that allowed us to compare all the picked up data and this increased, without doubt, the reliability of them.
  • The nasopharyngeal carcinoma is a tumor that usually affects young patients, of both sexes, without previous consumption of alcohol and tobacco and they are diagnosed in advanced stages.
  • [MeSH-major] Carcinoma. Nasopharyngeal Neoplasms
  • [MeSH-minor] Adult. Age Factors. Aged. Alcohol Drinking / adverse effects. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Data Interpretation, Statistical. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Nasopharynx / pathology. Risk Factors. Sex Factors. Smoking / adverse effects. Spain / epidemiology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12487069.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Chua DT, Sham JS, Au GK: A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. Head Neck; 2004 Feb;26(2):118-26
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
  • BACKGROUND: To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1.4 g/m2, ifosfamide, 450 mg/m2 5-fluorouracil, and 20 mg/m2 leucovorin daily for 5 days and repeated every 3 weeks for three cycles.
  • Radiotherapy was given using standard fractionation at 2 Gy/day to a total of 68 Gy to the nasopharynx and 66 Gy to the neck.
  • Twenty-three patients (66%) completed all scheduled cycles of chemotherapy.
  • The compliance rate for concurrent and adjuvant chemotherapy was 71% and 80%, respectively.
  • Grade 3 neutropenia occurred in 17% during concurrent chemotherapy, and grade 3-4 neutropenia occurred in 48.5% during adjuvant chemotherapy.
  • There were no treatment-related deaths.
  • Eleven patients (31%) had developed distant metastases, and the 3-year distant metastasis-free rate was 66%.
  • CONCLUSIONS: The chemotherapy regimen tested is practical with an acceptable compliance rate.
  • Despite having a more advanced stage disease, the observed outcome of our patients seems to be comparable with other series using platinum-based adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma / drug therapy. Carcinoma / radiotherapy. Ifosfamide / administration & dosage. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Dermatitis / etiology. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leukopenia / etiology. Male. Middle Aged. Survival Rate. Vomiting / etiology

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc. Head Neck 26: 118-126, 2004
  • (PMID = 14762880.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


6. Lee CC, Chu ST, Chou P: Concurrent chemoradiotherapy with adjuvant chemotherapy for high-risk nasopharyngeal carcinoma. Auris Nasus Larynx; 2009 Dec;36(6):688-94
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with adjuvant chemotherapy for high-risk nasopharyngeal carcinoma.
  • OBJECTIVES: To evaluate the impact of invasion of the prevertebral or parapharyngeal spaces and large tumor volume on treatment outcomes in patients with nasopharyngeal carcinoma (NPC).
  • All patients received a total dose of 70-75 Gy.
  • RESULTS: After controlling for age, sex, and chemotherapy status, invasion of the prevertebral or parapharyngeal spaces and large primary tumor volume produced a significantly increased hazard ratio for distant metastasis and recurrence.
  • We defined patients with two or more such prognostic factors as high-risk patients, in whom the 3-year metastasis-free survival rate, with and without adjuvant chemotherapy, was 100% and 69.6%, respectively (P=0.02).
  • Their 3-year recurrence-free survival rate, with and without adjuvant chemotherapy, was 93.3% and 70.2% (P=0.09).
  • CONCLUSION: NPC patients with any two or more of the factors, involvement of the prevertebral space, large primary tumor volume, or advanced parapharyngeal space invasion, had more recurrence and poor survival rates and benefited from concurrent chemoradiotherapy followed by adjuvant chemotherapy.
  • [MeSH-major] Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Nasopharynx / pathology. Neoplasm Invasiveness. Neoplasm Staging. Pharynx / pathology. Prognosis. Proportional Hazards Models. Radiotherapy Dosage. Retrospective Studies. Tumor Burden / drug effects. Tumor Burden / radiation effects. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410399.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Park KH, Kim JS, Park Y, Seo HY, Park YJ, Choi IK, Oh SC, Seo JH, Kim CY, Jung KY, Shin SW, Kim YH, Kim JS, Lee NJ: Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea. Cancer Chemother Pharmacol; 2010 Sep;66(4):643-51
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea.
  • PURPOSE: Concomitant approach using cisplatin and 5-fluorouracil (5-FU) has shown an excellent local control rate and significantly reduced distant metastasis in patients with locally advanced nasopharyngeal carcinoma (NPC).
  • However, optimal schedule and dosing of chemotherapy still need to be developed to reduce distant metastasis.
  • This retrospective study was conducted to evaluate the efficacy, toxicity, and tolerability of a concurrent chemoradiation therapy (CCRT) regimen using cisplatin and 5-FU followed by adjuvant chemotherapy (AC) in patients with locoregionally advanced NPC.
  • The chemotherapy during CCRT consisted of cisplatin (75 mg/m(2) on day 1) plus 5-FU (750 mg/m(2)/day on day 1-5), delivered every 4 weeks for two cycles.
  • CONCLUSIONS: CCRT regimen using cisplatin and 5-FU followed by three cycles of BEC chemotherapy was effective in locally advanced NPC patients, with acceptable and reversible acute toxicities.
  • [MeSH-major] Combined Modality Therapy. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease Progression. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Epirubicin / administration & dosage. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lymph Nodes / pathology. Male. Middle Aged. Nasopharynx / pathology. Neoplasm Recurrence, Local. Patient Compliance. Republic of Korea. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033411.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Kalyani A, Rohaizak M, Cheong SK, Nor Aini U, Balasundaram V, Norlia A: Recurrent multiple myeloma presenting as a breast plasmacytoma. Med J Malaysia; 2010 Sep;65(3):227-8
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a patient with multiple myeloma, who initially responded to chemotherapy and went into remission.
  • Further treatment with radiotherapy, thalidomide and later second line chemotherapy appeared unsuccessful and she showed rapid disease progression with rising paraproteins and new extramedullary plasmacytoma lesions in the forehead, supraclavicular region, nasopharynx, liver, spleen, pancreas and paraaortic lymph nodes.
  • [MeSH-major] Breast Neoplasms / pathology. Multiple Myeloma / pathology. Neoplasm Recurrence, Local / pathology. Plasmacytoma / pathology
  • [MeSH-minor] Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21939175.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


9. Song CH, Wu HG, Heo DS, Kim KH, Sung MW, Park CI: Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. Laryngoscope; 2008 Apr;118(4):663-70
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma.
  • OBJECTIVES: To analyze the impact of neoadjuvant chemotherapy (CT) on the treatment of early-stage nasopharyngeal carcinoma (NPC) as compared with radiotherapy (RT) alone.
  • RT was given to the nasopharynx and neck nodes.
  • The median dose to the primary site, involved nodes, and elective nodes was 70.2 Gy, 63 Gy, and 45 Gy, respectively.
  • RESULTS: The 5-year locoregional failure-free (LRFF), distant metastasis-free (DMF), disease-free survival (DFS), and overall survival (OS) rate was 84%, 93%, 81%, and 84% for the RT group and 77%, 86%, 71%, and 79% for the CT/RT group, respectively.
  • CONCLUSIONS: In our retrospective analysis, the use of neoadjuvant CT showed no additional benefit to treatment with RT alone.
  • [MeSH-major] Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy. Neoadjuvant Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Child. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymph Nodes / radiation effects. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18216741.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, Lu TX, Min HQ: Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol; 2005 Feb 20;23(6):1118-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials.
  • PURPOSE: To evaluate the long-term outcome in patients with nasopharyngeal carcinoma (NPC) treated with induction chemotherapy and radiotherapy (CRT) versus radiotherapy alone (RT).
  • Induction chemotherapy consisted of two to three cycles of cisplatin, bleomycin, and fluorouracil, or cisplatin and epirubicin.
  • RT was given to the nasopharynx and neck using megavoltage radiation (median dose, 70 Gy).
  • The median follow-up time for surviving patients was 67 months.
  • RESULTS: The addition of induction chemotherapy to RT was associated with a decrease in relapse by 14.3% and cancer-related deaths by 12.9% at 5 years.
  • The incidence of locoregional failure and distant metastases was reduced by 18.3% and 13.3% at 5 years, respectively, with induction chemotherapy.
  • There was no significant difference in the treatment failure patterns between the two arms.
  • CONCLUSION: The addition of cisplatin-based induction chemotherapy to RT was associated with a modest but significant decrease in relapse and improvement in disease-specific survival in advanced-stage NPC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local. Radiotherapy, High-Energy. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 20;23(6):1059-60 [15657407.001]
  • (PMID = 15657403.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


11. Hu QY, Liu P, Wang L, Fu ZF: [Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma]. Ai Zheng; 2007 Apr;26(4):394-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma].
  • BACKGROUND & OBJECTIVE: Most studies on chemoradiotherapy for advanced nasopharyngeal carcinoma (NPC) showed that induction chemotherapy before radiotherapy could not improve the survival of the patients, but the effect of adjuvant chemotherapy after radiotherapy on advanced NPC is uncertain.
  • This study was to evaluate the efficacy of concurrent chemoradiotherapy followed by adjuvant chemotherapy on stage III-IVa nasopharyngeal carcinoma (NPC).
  • Test group received concurrent chemotherapy of weekly cisplatin (25 mg/m2) for 6 weeks, and conventional radiotherapy of standard fractionation at 2 Gy/day to a total of 70 Gy to the nasopharynx, followed by adjuvant chemotherapy of cisplatin (25 mg/m2) and 5-fluorouracil (1000 mg/m2) daily for 3 days and repeated every 3 weeks for 3 cycles.
  • RESULTS: After treatment, 34 patients in test group and 32 in control group achieved complete remission (CR) (P>0.05); the CR rate of neck lymph node was significantly higher in test group than in control group (92.5% vs. 75.0%, P<0.05).
  • The 5-year distant metastasis rate was significantly lower in test group than in control group (15.0% vs. 35.0%, P<0.05).
  • CONCLUSION: Concurrent chemoradiotherapy followed by adjuvant chemotherapy could improve the CR rate of neck lymph node, overall survival, and disease-free survival of stage III-IVa NPC patients, suppress distant metastasis, but increase the risk of grade III mucositis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Nasopharyngeal Neoplasms / therapy. Radiotherapy, High-Energy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Mucositis / chemically induced. Neoplasm Staging. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430659.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Levendag PC, Lagerwaard FJ, Noever I, dePan C, vanNimwegen A, Wijers O, Schmitz PI, van Dieren E, Nowak PJ: Role of endocavitary brachytherapy with or without chemotherapy in cancer of the nasopharynx. Int J Radiat Oncol Biol Phys; 2002 Mar 1;52(3):755-68
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of endocavitary brachytherapy with or without chemotherapy in cancer of the nasopharynx.
  • PURPOSE: We previously reported our preliminary experience with nasopharyngeal cancer boosted after 60-70 Gy external beam radiotherapy (EBRT) by fractionated endocavitary brachytherapy (ECBT) to cumulative doses of 78-82 Gy.
  • As for Stage III-IVB disease, cisplatin (CDDP)-based neoadjuvant chemotherapy (CHT) was given.
  • METHODS AND MATERIALS: Ninety-one patients with primary nasopharyngeal cancer, staged according to the 1997 UICC/AJCC classification system, were treated between 1991 and 2000 with 60-70 Gy external beam radiotherapy and 11-18 Gy ECBT.
  • Treatment results were analyzed for local control (LC), disease-free survival (DFS), freedom from distant metastasis, and overall survival (OS).
  • RESULTS: A univariate and multivariate Cox regression analysis found stage, treatment period, age, and grade significant for LC, DFS, and OS.
  • For the 2nd treatment period (1996-2000; CHT for Stage III-IVB), the LC, DFS, and OS at 2 years was 100%, 90%, and 61% (Stage I-IIB), respectively, vs. 86%, 74%, and 66% (Stage III-IVB).
  • The results with 77-81 Gy without CHT warrant EBRT combined with ECBT to remain our standard of care for Stage I-IIB disease.
  • Because of better target coverage and sparing, T3-4 tumors are currently boosted by stereotactic RT to 81.2 Gy.
  • [MeSH-major] Brachytherapy / methods. Nasopharyngeal Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Dose Fractionation. Female. Fluorouracil / administration & dosage. Humans. Male. Neoplasm Staging. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11849799.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Saâdi I, El Marfany M, Hadadi K, Amaoui B, Kebdani T, Errihani H, Mansouri A, Benjaafar N, El-Gueddari BK: [Adenoid cystic carcinoma of the nasopharynx: a case report]. Cancer Radiother; 2003 Jun;7(3):190-4
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the nasopharynx: a case report].
  • [Transliterated title] Carcinome adénoïde kystique du nasopharynx: à propos d'un cas.
  • Nasopharyngeal adenoid cystic carcinoma is a rare tumor, few cases have been reported in the literature.
  • The aim of this report is to present a new case of an adenoid cystic carcinoma of the nasopharynx.
  • We report the case of a 50 years-old woman presenting with an adenoid cystic carcinoma of the nasopharynx with diffuse pulmonary metastasis.
  • The treatment combined chemotherapy, based on cisplatin and adriamycin drugs, and palliative radiation therapy at the dose of 30 Gy.
  • The patient died 6 months after diagnosis establishment.
  • The best treatment of adenoid cystic carcinoma is complete surgical resection but extended resection can be difficult in some locations as nasopharynx.
  • The adjuvant radiation therapy seems to improve local control.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Epistaxis / etiology. Fatal Outcome. Female. Headache / etiology. Humans. Middle Aged. Palliative Care. Prognosis. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12834776.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Koshy M, Paulino AC, Howell R, Schuster D, Halkar R, Davis L: The influence of F-18 FDG PET-CT fusion on radiotherapy treatment planning for head and neck cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):5534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of F-18 FDG PET-CT fusion on radiotherapy treatment planning for head and neck cancer.
  • MATERIALS AND METHODS: From July 2002 to Ocober 2003, 36 patients with intact primary HNC treated with radiation at the Emory Clinic received PET-CT fusion scans as part of treatment planning.
  • Primary site location was oropharynx in 17, nasopharynx in 5, larynx in 4, paranasal sinuses in 3, oral cavity in 2, hypopharynx in 2, and unknown primary in 3.
  • Platinum based chemotherapy was given concurrently with RT in 31 (86%).
  • CT and FDG -PET scans were obtained for radiotherapy treatment planning.
  • In the upstaged patients, T (tumor) stage only increased in 1, N(nodal) status increased in 1, both T and N increased in 1 and metastasis was found in 3 .
  • CONCLUSION: PET-CT fusion imaging has significant impact on staging, patient management and determination of the PTV and consequent radiotherapy treatment doses and volumes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Shehadeh NJ, Becker M, Yoo G, Lin HS, Jacobs J, Mathog R, Kucuk O, Kim H, Black C, Ensley J: Unknown head and neck primary: Treatment with neck dissection followed by concurrent chemoradiotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):5530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unknown head and neck primary: Treatment with neck dissection followed by concurrent chemoradiotherapy.
  • : 5530 Background:The best management of lymph node metastasis from unknown primary in the head and neck has not been clearly established.
  • METHODS: We conducted a retrospective evaluation of patients (pts) treated between 1995 and 2002 who had resectable nodal squamous cell cancer (SCC) of unknown primary sites and were treated with modified neck dissection followed by concurrent high-dose cisplatin (CIS) and radiotherapy (RT) using a port inclusive of the nasopharynx.
  • Chemotherapy was given as cisplatin 100mg/m<sup>2</sup> x 3 cycles in 86% or CIS=>carboplatin in 14 %.
  • Therapy was not completed in 14% of pts.
  • With median follow-up of 30 months (range 7-101 months), 88 % of pts were disease-free and 12 % failed treatment: loco-regional failure (3%), loco-regional and distant metastasis (3%), and distant metastasis (6%).
  • A second primary (tongue cancer) was seen in one patient and another patient developed colon cancer at 90 months and 18 months, respectively.
  • CONCLUSIONS: Neck dissection followed by chemo/RT, using high dose CIS concurrently with nasopharyngeal port RT, is an effective way of treating pts with SCC of neck from an unknown primary.
  • This treatment may confer an improved survival and warrants further prospective testing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013947.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Craig MD, Rogers JS, Gupta N: Evaluation of PET scan in small cell lung cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):7214

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prognosis, survival, and treatment options correlate with stage at diagnosis.
  • We hypothesize PET scanning may have a role in the staging procedure of patients with small cell lung cancer.
  • CT scan suggested adrenal metastasis in 4 patients, and opposite lung lesions in another, but the PET scan was not hypermetabolic.
  • All but one (who was lost to follow-up) were treated as limited stage disease with concurrent radiation and chemotherapy.
  • Two patients were increased from limited to extensive stage by PET scan results, one survived 9 months and the other is 5 months into therapy.
  • One patient had a biopsy proven false positive PET finding of lymphoid hyperplasia in the nasopharynx that would have increased the stage to extensive.
  • PET scan was insensitive to detect brain metastasis (40% sensitive), although this did not change the patients' stage.
  • A PET scan may be helpful to insure patients with small cell lung cancer are accurately staged and offered appropriate treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013807.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Yamouni M, Beldjillali Y, Benhadji KA, Lahfa I, Brahimi M, Ait-Said M, Djellali L, Bouzid K: A phase II trial of docetaxel and cisplatin combination in patients with locally advanced undifferentiated carcinoma of nasopharygeal type (UCNT). J Clin Oncol; 2004 Jul 15;22(14_suppl):5599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of docetaxel and cisplatin combination in patients with locally advanced undifferentiated carcinoma of nasopharygeal type (UCNT).
  • : 5599 Background: The standard treatment of locally advanced UCNT is chemotherapy followed by locoregional radiotherapy.
  • The purpose of this study is to assess the antitumor activity and toxicity of a new neoadjuvant chemotherapy regimen combining docetaxel (D) and cisplatin (C).
  • Pts were evaluated by clinical examination, nasofibroscopy with biopsy and CT scan of nasopharynx.
  • RESULTS: Toxicity, tumor response and survival over one year were assessable in all pts.
  • 18 patients had recurence: 16 locoregional, 1 hepatic metastasis and 1 cerebral metastasis.
  • The complete response after chemotherapy appear as an important factor predicting recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014049.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Lin IH, Hwang CF, Huang HY, Chien CY: Small cell carcinoma of the nasopharynx. Acta Otolaryngol; 2007 Feb;127(2):206-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the nasopharynx.
  • Both pulmonary and extrapulmonary small cell carcinomas usually have a good response to chemotherapy initially, but a poor prognosis finally.
  • We report here a case of small cell carcinoma of the nasopharynx.
  • The patient underwent chemotherapy and irradiation for the disease, but died of lung metastasis 38 months later.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / therapeutic use. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Etoposide / therapeutic use. Fatal Outcome. Humans. Male. Radiotherapy, Adjuvant

  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364353.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine; CBV protocol
  •  go-up   go-down


19. Yao K, Takahashi H, Inagi K, Nakayama M, Makoshi T, Nagai H, Okamoto M: Carcinoma of the nasopharynx: analysis of treatment results in 91 patients. Acta Otolaryngol Suppl; 2002;(547):20-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the nasopharynx: analysis of treatment results in 91 patients.
  • The outcome of 91 patients (69 males, 22 females; age range 16-82 years) with nasopharyngeal carcinoma treated in our hospital between 1971 and 1999 was evaluated.
  • The disease-free cumulative 3-year survival rates of the patients classified based on initial therapy were as follows: radiation alone, 50.0% (n = 28); combined radiotherapy and chemotherapy that included an undefined anti-cancer drug, 67.2% (n = 39); combined radiotherapy and chemotherapy that included carboplatin (CBDCA), 92.3% (n = 19).
  • We conclude that combined therapy, including chemotherapy with CBDCA, is necessary for the treatment of nasopharyngeal carcinoma.
  • In terms of radiation therapy, a field covering the bilateral cervical regions seemed to produce favorable results, even if cervical node metastasis was not confirmed by palpation at the first hospital visit.
  • Key words: carboplatin, chemotherapy,
  • [MeSH-major] Carcinoma / mortality. Carcinoma / therapy. Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / therapy. Outcome Assessment (Health Care) / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Protocols. Female. Hospitals, University / statistics & numerical data. Humans. Japan. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Severity of Illness Index. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12212588.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


20. Tagawa T, Tomita T, Yamaguchi H, Ozawa H, Sakamoto K, Ogawa K, Fujii M: [Clinical study of 28 cases of cervical lymph node metastasis from an unknown primary carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2007 Jul;110(7):506-12
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of 28 cases of cervical lymph node metastasis from an unknown primary carcinoma].
  • From 1989 to 2005, 28 patients--20 men and 8 women--with cervical lymph node metastasis from an unknown primary carcinoma were treated and studied retrospectively.
  • In histological diagnosis, open biopsy was conducted in 11 patients and non-open biopsy (FNA or frozen section diagnosis during surgery) in 17.
  • Blind biopsy under general anesthesia was conducted in 10 patients, showing one primary tumor in the nasopharynx.
  • Tonsillectomy for diagnosis was not done.
  • In region of maximum-size lymph node metastasis, the upper cervical region accounted for 22 cases (79%).
  • The histopathological diagnosis of cervical lymph node was as follows: squamous cell carcinoma in 21, adenocarcinoma in 3, mucoepidermoid carcinoma in 2, and others in 2.
  • Therapy was as follows: only neck dissection in 7, neck dissection with postoperative radiation therapy in 13, and irradiation and chemotherapy in 8.
  • All patients treated with irradiation and chemotherapy had been judged to be inoperable.
  • Seven patients were found to have a subsequent primary tumor.
  • Primary tumor sites were as follows: tonsils in 3 and upper gingiva, base of tongue, lung, and nasopharynx in 1 each.
  • FDG-PET was conducted in 7 patients but revealed no primary tumor.
  • We should pay particular attention to the tonsils for detecting primary tumors in patients with cervical metastasis from an unknown primary carcinoma.
  • [MeSH-major] Head and Neck Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695298.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. Peng RQ, Wu GH, Chen WK, Ding Y, Ma J, Zhang NH, Su YS, Zhang XS: [Clinical characteristics and prognosis of primary nasal mucosal melanoma--a report of 44 cases]. Ai Zheng; 2006 Oct;25(10):1284-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Primary mucosal malignant melanoma of the nasal cavity, paranasal sinuses, and nasopharynx is rare and current research data of this disease are mainly from western populations.
  • Demographics and baseline characteristics, treatments, recurrence, metastasis, and survival were documented in hospital records.
  • RESULTS: Among 44 evaluable cases, 37 were originated from the nasal cavity, 5 from the paranasal sinuses, and 2 from the nasopharynx.
  • Of the 31 patients received operation-dominated treatment, 8 received adjuvant radiotherapy, 13 received adjuvant chemotherapy, and 6 received adjuvant non-specific immunotherapy.
  • The median time of follow-up was 29 months.
  • Local recurrence, cervical lymphadenopathy, and distant metastasis occurred in 24, 10, and 11 patients, respectively, during follow-up.
  • The median survival time was 24 months and the 5-year survival time was 25%.
  • Clinical stage affected prognosis, whereas age, gender, site, primary tumor mass, and adjuvant therapy were not correlated to survival status.
  • CONCLUSION: Nasal mucosal melanoma has high incidence of local recurrence and distant metastasis, especially cervical lymphadenopathy.
  • [MeSH-major] Melanoma. Nasal Mucosa. Neoplasm Recurrence, Local. Nose Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Nasal Cavity. Neoplasm Staging. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059777.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


22. Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT: Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):410-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
  • PURPOSE: To review the University of Iowa experience with intensity-modulated radiotherapy (IMRT) in the treatment of head-and-neck squamous cell carcinoma.
  • One patient was lost to follow-up 2 months after treatment and therefore excluded from analysis.
  • Of the remaining 150 patients, 99 were treated with definitive IMRT, and 51 received postoperative IMRT.
  • Sites included were nasopharynx, 5; oropharynx, 56; larynx, 33; oral cavity, 29; hypopharynx, 8; nasal cavity/paranasal sinus, 8; and unknown primary, 11.
  • None of the patients treated with postoperative IMRT received chemotherapy.
  • Of 99 patients who had definitive IMRT, 68 patients received concurrent cisplatin-based chemotherapy.
  • One patient received induction cisplatin-based chemotherapy, but no concurrent chemotherapy was given.
  • The prescribed doses to CTV1, CTV2, and CTV3 in the definitive cohort were 70-74 Gy, 60 Gy, and 54 Gy, respectively.
  • For high-risk postoperative IMRT, the prescribed doses to CTV1, CTV2, and CTV3 were 64-66 Gy, 60 Gy, and 54 Gy, respectively.
  • For intermediate-risk postoperative IMRT, the prescribed doses to CTV1, CTV2, and CTV3 were 60 Gy, 60 Gy, and 54 Gy.
  • There were 11 local-regional failures: 7 local failures, 3 regional failures, and 1 failure both in the primary tumor and regional lymph node.
  • There were 16 patients who failed distantly, either with distant metastasis or new lung primaries.
  • The median time from treatment completion to local-regional recurrence was 4.7 months (range, 1.8 to 15.6 months).
  • Only one marginal failure was noted in a patient who had extensive tonsil cancer with tumor extension into the orbit and cavernous sinus.
  • There was no significant difference in local-regional control for patients who received postoperative radiation or definitive radiation (p = 0.339) and for patients who had chemotherapy or not (p = 0.402).
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Iowa. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Treatment Failure. Universities

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168834.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Guo L, Lin HX, Li FY, Li Q, Qiu F, Luo DH, Guo X, Hong MH: [Phase I study of capecitabine with concurrent radiotherapy in early-stage nasopharyngeal carcinoma]. Zhonghua Zhong Liu Za Zhi; 2004 Apr;26(4):250-3
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phase I study of capecitabine with concurrent radiotherapy in early-stage nasopharyngeal carcinoma].
  • OBJECTIVE: To evaluate the dose-limiting toxicity (DLT), efficacy and maximum tolerated dose (MTD) of capecitabine with concurrent radiotherapy in patients with node-positive stage II nasopharyngeal cancer.
  • METHODS: From August 2002 to June 2003, 30 patients with node-positive stage II T(2)N(1)M(0) nasopharyngeal cancer were retrospectively reviewed.
  • Radiotherapy of 68 - 72 Gy/34 - 36 fractions was delivered to the nasopharynx and 64 - 70 Gy/32 - 35 fractions to the node-positive area.
  • Capecitabine was administered orally on day 1 of radiotherapy by an intermittent schedule (14 days treatment; 7-day rest) at 3 weekly intervals for two cycles.
  • Dose escalation was done after six patients had completed 2 cycles of chemotherapy at the previous dose level with DLT assessed.
  • The CR response rate of the node-positive area and of the nasopharynx were 50.0% (14/28) and 46.4% (13/28).
  • This regimen is tolerable and valid for nasopharyngeal carcinoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Capecitabine. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Fluorouracil / analogs & derivatives. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Stomatitis / chemically induced. Thrombocytopenia / chemically induced

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15312392.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Yariş N, Kutluk T, Yalçin B, Akyüz C, Büyükpamukçu M: Nasal-paranasal-oronasopharyngeal lymphomas in childhood: the role of staging system on prognosis. Pediatr Hematol Oncol; 2000 Jul-Aug;17(5):345-53
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the patients with nasal-paranasal and oropharyngeal-nasopharyngeal (NPONP) lymphomas had early-stage disease according to the Murphy system.
  • Treatment results were analyzed to see the effects of the staging in NPONP lymphomas.
  • The Murphy staging system was used at diagnosis and all cases were restaged according to the TNM system: primary tumor, regional lymph node, and metastasis.
  • The survival rates were analyzed by grouping the patients according to the treatment and stages.
  • The disease was located in Waldeyer's ring, the sinonasal region, and the nasopharynx in 45.4, 27.3, and 27.3% of patients, respectively.
  • Treatment protocols were intensified in most of the early-stage disease treated with modified LSA2-L2 regimen and better survival rates were obtained in these patients.
  • The intensification of the treatment by using intrathecal treatment and doxorubicin in patients with early-stage disease at NPONP location seems effective.
  • It should be revised to predict the prognosis and decision-making for treatment.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Nose Neoplasms / diagnosis. Pharyngeal Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / secondary. Central Nervous System Neoplasms / secondary. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / pathology. Neoplasm Staging. Oropharyngeal Neoplasms / diagnosis. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / pathology. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / pathology. Prednisone / administration & dosage. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Hematol Oncol. 2000 Oct-Nov;17(7):517-20 [11033725.001]
  • (PMID = 10914044.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; LSA2-L2 protocol
  •  go-up   go-down


25. Khanfir A, Frikha M, Ghorbel A, Karray H, Drira MM, Daoud J: [Metastatic nasopharyngeal carcinoma: clinical study and therapeutic results of 95 cases]. Cancer Radiother; 2006 Dec;10(8):545-9
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic nasopharyngeal carcinoma: clinical study and therapeutic results of 95 cases].
  • [Transliterated title] Les cancers métastatiques du nasopharynx: étude clinique et résultats thérapeutiques de 95 cas.
  • PURPOSE: The objective of this retrospective study was to discuss the epidemioclinical criteria and the therapeutic results of metastatic nasopharyngeal carcinoma.
  • PATIENTS AND METHODS: The current study concerned 95 patients with histologically proven nasopharyngeal carcinoma who were metastatic at diagnosis or who had developed late metastasis.
  • Patients were treated with chemotherapy (BEC regimen: bleomycin, epirubicin and cisplatin or PBF regimen: bleomycin, 5-fluorouacil and cisplatin) and radiotherapy of pauci metastatic localizations (single or double) or bone metastasis with high risk of compression or fracture+/-associated with locoregional radiotherapy for patients who were metastatic at diagnosis.
  • RESULTS: There were 34 patients who were metastatic at diagnosis and 61 patients who had developed late metastasis.
  • Twenty-five patients received radiotherapy for pauci metastatic localizations, among whom 19 patients who were metastatic at diagnosis received locoregional irradiation.
  • CONCLUSION: Therapeutic results were comparable to those reported in other series using platin combination chemotherapy.
  • Radiotherapy of metastasis yielded to long-term survival.
  • [MeSH-major] Nasopharyngeal Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bone Neoplasms / secondary. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807035.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Kruk-Zagajewska A, Szmeja Z, Wierzbicka M: [Neck metastases from unknown primary neoplasms (CUP syndrome)]. Otolaryngol Pol; 2000;54 Suppl 31:262-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoma of unknown primary (CUP-syndrome) is taken into consideration when the patient has histologically confirmed metastases but the primary focus remains unknown or it's diagnosis is delayed.
  • Diagnostic procedures applied in detection of primary foci have been described.
  • The knowledge of lymphatic metastases spreading routes is helpful in the primary focus detection.
  • In the remaining 15 patients the primary was located in nasopharynx, palatinal tonsil, tongue, hypopharynx, testes or breast.
  • The treatment included the radical neck dissection with consecutive irradiation and/or chemotherapy, and in the case of diagnosing the primary one applied it's radical removal or radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Neoplasms, Unknown Primary
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymph Nodes / surgery. Lymphatic Metastasis. Male. Middle Aged. Neck

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974902.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] POLAND
  •  go-up   go-down


27. Frikha M, Toumi N, Ghorbel L, Ben Salah H, Khabir A, Karray H, Gargouri R, Boudawara T, Ghorbel A, Daoud J: [Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities]. Cancer Radiother; 2010 Jun;14(3):169-75
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities].
  • [Transliterated title] Le cancer du cavum de l'enfant et l'adulte jeune : aspects anatomocliniques, thérapeutiques et particularités évolutives.
  • PURPOSE: We retrospectively analyzed anatomoclinic, therapeutic and evolutive particularities of 74 young patients (< or =20 years) with nasopharyngeal carcinoma treated between 1993 and 2005.
  • PATIENTS AND METHODS: Initial work-up included a fiberoptic nasofibroscopy with biopsy, tomodensitometry and/or MRI of nasopharynx and neck, chest X-ray, abdominal ultrasonography and bone scan.
  • Patients were treated with either primary chemotherapy (epirubicin and cisplatin) followed by radiotherapy or concomitant radiochemotherapy (five fluorouracil and cisplatin).
  • Radiotherapy was delivered to a total dose of 70 to 75 Gy to nasopharynx and involved cervical lymph nodes and 50 Gy to the remainder cervical areas.
  • Sixty-six percent had locally advanced tumor.
  • With a median follow-up of 107 months, one patient presented a local relapse, 24 patients developed distant metastases with a median delay of 7 months.
  • COMMENTS: Pediatric nasopharyngeal carcinoma is characterized by an early metastatic diffusion.
  • New techniques of radiotherapy and new molecules of chemotherapy could improve these results.
  • [MeSH-major] Carcinoma / epidemiology. Cobalt Radioisotopes / therapeutic use. Nasopharyngeal Neoplasms / epidemiology. Radioisotope Teletherapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Child. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / etiology. Radiotherapy, Conformal. Retrospective Studies. Treatment Outcome. Xerostomia / epidemiology. Xerostomia / etiology. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010. Published by Elsevier SAS.
  • (PMID = 20347607.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Shen C, Gao Y, Xu T, Wang X, Ying H, Hu C: Carcinoma of the nasopharynx in young patients: a single institution experience. Clin Oncol (R Coll Radiol); 2009 Oct;21(8):617-22
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the nasopharynx in young patients: a single institution experience.
  • AIMS: Nasopharyngeal carcinoma (NPC) is rare in young patients.
  • Seventeen patients received radiotherapy alone and 25 had cisplatin-based chemotherapy additionally.
  • The radiation dose to the primary tumour and involved nodes was 64-74 Gy.
  • Patients with N0-1 had a lower distant metastasis rate compared with patients with N2-3, and the TNM stage grouping was found to be a marginally important prognostic factor for disease-free survival.
  • The addition of chemotherapy failed to be of therapeutic value.
  • [MeSH-major] Carcinoma / therapy. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Disease-Free Survival. Female. Humans. Male. Nasopharynx / pathology. Neoplasm Metastasis. Radiotherapy Dosage. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19660923.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Kubota A, Furukawa M, Kawano T, Komatsu M: [Nedaplatin for recurrent cancer of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2004 May;107(5):475-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-two patients, previously treated, (30 men and 2 women, mean age 59 years, twenty one with loco-regional recurrence and 11 with distant metastasis, 29 with squamous cell carcinoma, 2 with adenocarcinoma and one with adenoid cystic carcinoma) were treated with Nedaplatin (254-S) alone or combined with UFT.
  • The primary site was identified in the oropharynx in 8 patients, oral cavity in 7, larynx in 5, nasopharynx in 4, hypopharynx in 3, sinuses in one, parotid in one, and unknown primary in one patient.
  • Ten of the eleven patients with distant metastasis died within six months and all patients were dead within 18 months, so a significant difference was observed in the overall survival rate between loco-regional recurrence and distant metastasis.
  • Treatment with 254-S alone or combined UFT-E could be conducted in an outpatient setting and was able to improve the overall survival rate for recurrent head and neck cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Male. Middle Aged. Survival Rate. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15198007.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 8UQ3W6JXAN / nedaplatin; 1-UFT protocol
  •  go-up   go-down


30. Chua DT, Sham JS, Au GK, Choy D: Concomitant chemoirradiation for stage III-IV nasopharyngeal carcinoma in Chinese patients: results of a matched cohort analysis. Int J Radiat Oncol Biol Phys; 2002 Jun 1;53(2):334-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chemoirradiation for stage III-IV nasopharyngeal carcinoma in Chinese patients: results of a matched cohort analysis.
  • PURPOSE: To evaluate the toxicity and efficacy of concomitant chemoirradiation (CRT) followed by adjuvant chemotherapy compared with radiotherapy (RT) alone in Chinese patients with locoregionally advanced nasopharyngeal carcinoma (NPC).
  • METHODS AND MATERIALS: Between March 1997 and September 2000, 47 Chinese patients with Stage III (n = 9, 19%) and IV (n = 38, 81%) NPC were treated with by CRT using cisplatin 100 mg/m(2) on Days 1, 22, and 43 of RT, plus adjuvant chemotherapy using cisplatin 80 mg/m(2) for 1 day and 5-fluorouracil 1 g/m(2) for 4 days on Days 71, 99, and 127.
  • The median biologic equivalent dose to 2 Gy per fraction delivered to the nasopharynx was 68 Gy in the CRT group and 65.3 Gy in the RT-alone group.
  • RESULTS: The compliance rates were 62% for concomitant chemotherapy and 40% for adjuvant chemotherapy.
  • No treatment-related deaths occurred.
  • At the end of treatment, 96% of the CRT group and 79% of the RT-alone group achieved a complete response (p = 0.013).
  • With a median follow-up of 26 months, the 3-year relapse-free survival, disease-specific survival, overall survival, local relapse-free survival, nodal relapse-free survival, and distant metastasis-free survival rate for the CRT group and the RT-alone group was 62% vs. 44% (p = 0.048), 67% vs. 71% (p = 0.88), 65% vs. 69% (p = 0.93), 87% vs. 75% (p = 0.059), 95% vs. 80% (p = 0.026), and 75% vs. 70% (p = 0.84), respectively.
  • The failure to reduce distant metastasis and improve survival may have related in part to the more advanced disease stage in our patients and the relatively low compliance rate of adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cohort Studies. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Male. Middle Aged. Neck Dissection. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Patient Compliance. Radiotherapy Dosage. Salvage Therapy

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12023137.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors of the nasal cavity and paranasal sinuses.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • RESULTS: The 5-year actuarial local control rate for stage I (limited to the site of origin; 22 patients) was 86%; for stage II (extension to adjacent sites (eg, adjacent sinuses, orbit, pterygomaxillary fossa, nasopharynx; 21 patients) was 65%; and for stage III (destruction of skull base or pterygoid plates, or intracranial extension; 35 patients) was 34%.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • Twenty-one (27%) of 78 patients had unilateral blindness develop secondary to radiation retinopathy or optic neuropathy; the complication was anticipated in most of these patients, because the ipsilateral eye was irradiated to a high dose.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Issing PR, Hemmanouil I, Wilkens L, Karstens H, Lenarz T: [Long term results in adenoidcystic carcinoma]. Laryngorhinootologie; 2002 Feb;81(2):98-105
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The exact distribution of the ACC was: parotid gland (n = 18), submandibular gland (n = 8), oral cavity (n = 10), paranasal sinuses (n = 11), nasopharynx (n = 4) and larynx (n = 3).
  • The most common symptoms were a tumor-related swelling and pain which persisted for a duration of several months after final diagnosis could be established.
  • No definitive differentiation was possible in 10 specimens.
  • Except one patient all 54 underwent surgical therapy.
  • Postoperative radiotherapy was additionally given in 25 cases which was combined with a chemotherapy in 6 patients.
  • Lymphnode metastases were observed in 13 patients after a latency of 3.3 years in average, but predominantly pulmonary metastases as distant spread developed in 18 patients after 5.8 years significantly later.
  • CONCLUSIONS: Due to the uncommon biological behaviour with a slow growth on the one hand side and an aggressive local invasion on the other hand side the ACC can be regarded as a challenging malignant disease for the clinician whose adequate therapy does not allow any standardized regime.
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / surgery. Laryngeal Neoplasms / therapy. Lymphatic Metastasis. Male. Middle Aged. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / surgery. Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local. Parotid Neoplasms / diagnosis. Parotid Neoplasms / surgery. Parotid Neoplasms / therapy. Prognosis. Retrospective Studies. Submandibular Gland. Time Factors

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11914946.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Chen HH, Tsai ST, Wang MS, Wu YH, Hsueh WT, Yang MW, Yeh IC, Lin JC: Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys; 2006 Dec 1;66(5):1408-14
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma.
  • PURPOSE: Radiotherapy is the most effective treatment for nasopharyngeal carcinoma (NPC).
  • The aim of this study is to evaluate the efficacy and toxicity of fractionated stereotactic body radiation therapy (SBRT) boost for NPC.
  • METHODS AND MATERIALS: Sixty-four patients with newly diagnosed, nonmetastatic NPC were treated with conventional radiotherapy 64.8-68.4 Gy followed by fractionated SBRT boost 12-15 Gy between January 2002 and July 2004.
  • Fifty-two patients also received cisplatin-based concurrent (38) or neoadjuvant (14) chemotherapy.
  • After a median follow-up of 31 months (range, 22-54), 15 patients developed tumor recurrences--3 in the nasopharynx, 4 in the neck, 5 in distant sites, 1 in both nasopharynx and neck, 2 in the neck and a distant site.
  • The 3-year actuarial rate of local control was 93.1%, regional control 91.4%, freedom from distant metastasis 90.3%, and overall survival 84.9%, respectively.
  • [MeSH-major] Carcinoma / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy. Stereotaxic Techniques
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1584-5; author reply 1585 [17674997.001]
  • (PMID = 17126207.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Ijichi K, Hasegawa Y, Ogawa T, Terada A, Hyodo I, Yamada H, Murakami S: [Investigation for cervical lymph node metastasis in unknown primary sites]. Nihon Jibiinkoka Gakkai Kaiho; 2005 Nov;108(11):1083-90
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Investigation for cervical lymph node metastasis in unknown primary sites].
  • In patients with cervical adenopathy, especially, those of cervical lymph node metastasis with no detectable primary tumor, diagnosis and treatment planning can become confused.
  • We evaluated 36 patients with cervical lymph node metastasis of unknown origin between 1985 and 2002.
  • Primary sites were detected in 20 before treatment.
  • The other 36 patients clearly had no primary lesions when treatment started.
  • Primary sites were 5 cases of oropharynx, 2 of the parotid gland, and 1 each of larynx, nasopharynx, hypopharynx, and malignant lymphoma detected in 11 after treatment for cervical lymph nodes.
  • Biopsy sites were the nasopharynx, palatine and lingual tonsil, and piriform sinus.
  • Chemotherapy and radiotherapy were the treatment of choice in many cases.
  • The primary site cannot be detected, treatment should initially involve cervical adenopathy with combined surgery, chemotherapy, and radiotherapy.
  • After treatment, the patient should be followed up carefully to find the primary lesion.
  • [MeSH-minor] Biopsy, Needle. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16359003.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Nascimento AF, Fletcher CD: Spindle cell rhabdomyosarcoma in adults. Am J Surg Pathol; 2005 Aug;29(8):1106-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor size varied from 1.5 to 35 cm (median, 6 cm).
  • The head and neck region, including the oral cavity, parotid gland, nasopharynx, and nasal cavity, was the commonest affected area, accounting for >50% of the cases, followed by retroperitoneum, thigh, leg, subscapular area, hand, vulva, and paratesticular region (1 case each).
  • Treatment modalities included surgery, chemotherapy, and radiation.
  • Two patients died of uncontrolled local disease 13 and 27 months after diagnosis; 4 were alive without disease at 12, 17, 24, and 102 months, including 1 patient with metastasis to 10 of 50 pelvic lymph nodes at presentation; 3 are alive with localized disease at 16, 17, and 19 months; and 1 was followed for 6 months and showed persistent local disease.
  • One patient is alive at 10 months after diagnosis with evidence of metastatic disease to bone, lungs, and breast.
  • One tumor was focally positive for keratins and EMA.
  • Spindle cell RMS is a rare neoplasm in adults and appears to have distinct clinicopathologic features when compared with cases occurring in the pediatric population.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006807.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Myogenic Regulatory Factors; 0 / Myoglobin; 0 / S100 Proteins; 0 / myogenic factor 6; 68238-35-7 / Keratins; EC 3.6.4.1 / Myosins
  •  go-up   go-down


36. Gil Z, Fliss DM: Contemporary management of head and neck cancers. Isr Med Assoc J; 2009 May;11(5):296-300
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HNCs can originate in the skin or soft tissue, in the upper aerodigestive tracts (oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, paranasal sinuses, salivary glands), or in the thyroid.
  • In each of these sites, tumors vary not only by the primary site but also by pathophysiology, biological behavior, and sensitivity to radiotherapy or chemotherapy.
  • Management should be planned according to the tumor's characteristics, patient factors and expertise of the medical team.
  • The main goals of therapy are ablation of the cancer while minimizing morbidity and preserving function and cosmesis.
  • Early-stage HNC (stage I and II) should be managed with a single modality, and advanced tumors (stage III and IV) with multimodality therapy.
  • Treatment should be directed to the primary tumor and the area of its lymphatic drainage--the neck lymph nodes.
  • [MeSH-major] Head and Neck Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Lymphatic Metastasis. Neck Dissection. Prognosis. Quality of Life. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637508.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Israel
  • [Number-of-references] 29
  •  go-up   go-down


37. Megat Shiraz MA, Jong YH, Primuharsa Putra SH: Extramedullary plasmacytoma in the maxillary sinus. Singapore Med J; 2008 Nov;49(11):e310-1
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extramedullary plasmacytoma is a rare malignant plasma cell tumour.
  • Nasendoscopy revealed a medialised medial wall of the right maxilla and a mass occupying the whole nasopharynx.
  • Magnetic resonance imaging revealed a right maxillary tumour with extension to the ipsilateral nasal cavity, nasopharynx, right sphenoid and ethmoidal sinuses.
  • There was an extra-axial brain metastasis.
  • He was planned for four cycles of chemotherapy.
  • Unfortunately, in view of the advanced stage of disease, he succumbed to his disease during the first cycle of chemotherapy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Maxillary Sinus Neoplasms / diagnosis. Maxillary Sinus Neoplasms / radiography
  • [MeSH-minor] Anemia / complications. Antineoplastic Agents / therapeutic use. Fatal Outcome. Humans. Magnetic Resonance Imaging / methods. Male. Maxillary Sinus / pathology. Maxillary Sinus / radiography. Middle Aged. Nasopharynx / pathology. Neoplasm Metastasis. Plasmacytoma / diagnosis. Plasmacytoma / pathology. Plasmacytoma / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037537.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


38. Kalogera-Fountzila A, Karanikolas D, Katodritis N, Samantas E, Sarafopoulos A, Ikonomou I, Zamboglou N, Tselis N, Dimitriadis AS, Fountzilas G, AJCC (American Joint Committee on Cancer): Prognostic factors and significance of the revised 6th edition of the AJCC classification in patients with locally advanced nasopharyngeal carcinoma. Strahlenther Onkol; 2006 Aug;182(8):458-66
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and significance of the revised 6th edition of the AJCC classification in patients with locally advanced nasopharyngeal carcinoma.
  • PURPOSE: To compare the 4th edition 1992 and 6th edition 2002 of the American Joint Committee on Cancer (AJCC) staging systems, to evaluate the paranasopharyngeal structures and lymph node involvement, and to define the prognostic significance of the above factors to overall survival (OS) in patients with locally advanced nasopharyngeal carcinoma (NPC).
  • PATIENTS AND METHODS: CT images of 162 patients, who were diagnosed with NPC and received irradiation alone or chemotherapy and irradiation, were retrospectively reviewed.
  • CT scans, performed prior to and after the completion of treatment, were reviewed.
  • 50 of 162 patients (31%) displayed parapharyngeal extension of the tumor to degree A, 59 patients (36%) showed degree B, and 50 patients (31%) degree C nasopharyngeal extension.
  • The degree of tumor extension into the parapharyngeal space should be considered in future TNM staging revisions.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / pathology. Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / pathology. Nasopharynx / pathology. Neoplasm Staging
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Combined Modality Therapy. Confidence Intervals. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Prognosis. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896592.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. Lu JJ, Shakespeare TP, Tan LK, Goh BC, Cooper JS: Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma. Head Neck; 2004 May;26(5):389-95
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
  • BACKGROUND: The value of high-dose-rate intracavitary brachytherapy (HDRIB) for persistent or recurrent nasopharyngeal carcinoma has been well described; however, the benefit of routine adjuvant fractionated HDRIB following external beam radiation therapy (EBRT) has not been completely determined.
  • The objective of this analysis was to evaluate the outcome of two fractions of adjuvant HDRIB treatment in Tl and T2 nasopharyngeal carcinoma.
  • METHODS: Thirty-three consecutive and nonselected patients who had Tl and T2 non-disseminated nasopharyngeal carcinoma were treated according to an IRB approved institutional research protocol between March 1999 and July 2001.
  • Seventeen of these patients who had stage I or stage II disease (i.e., NO or Nl) were treated with EBRT followed by two fractions of adjuvant HDRIB (group 1); 16 patients who had stage III or stage IV disease (i.e., N2 or N3) were treated with concurrent cisplatin, EBRT and adjuvant HDRIB and subsequent adjuvant cisplatin and fluorouracil (5-FU) chemotherapy (group 2).
  • EBRT was delivered by daily conventional fractionation to a total dose of 66 Gy to the primary tumor.
  • Nodal disease received 66 Gy if it was less than 3 cm in maximum diameter and 70 Gy if larger or there was palpable residual disease after 66 Gy.
  • A total of 10 Gy of HDRIB in 2 equal fractions of 5 Gy spaced 1 week apart was delivered starting 1 week after the completion of EBRT.
  • All patients were assessed for treatment response, local control, survival, and toxicity.
  • One patient died 7 months and one died 18 months after radiation therapy from the effects of distant metastases; two died of unrelated causes.
  • At the time of this analysis, one patient (3%) had persistent local disease and one patient (3%) developed pathologically confirmed local recurrence in the nasopharynx.
  • In addition, one patient (3%) developed recurrence only in a neck node followed by distant metastasis, and two patients (6%) developed distant metastasis without locoregional relapse.
  • All patients experienced some degree of acute and/or late toxicity related to radiation therapy.
  • Ten patients (30%) experienced grade 3 acute and/or late toxicity and six patients (18%) developed grade 4 acute and/or late toxicity.
  • CONCLUSIONS: EBRT supplemented by two fractions of adjuvant HDRIB produced a 93.6% local control rate for Tl and T2 nasopharyngeal cancer at 2 years of follow up, with acceptable rates of acute and late toxicity.
  • Brief adjuvant HDRIB appears to permit dose escalation safely, even in patients who receive chemotherapy concurrently with conventional radiation therapy.
  • [MeSH-major] Brachytherapy / methods. Carcinoma / pathology. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Radiotherapy Dosage. Radiotherapy, Adjuvant. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc. Head Neck 26: 389-395, 2004.
  • (PMID = 15122654.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Raney B, Anderson J, Breneman J, Donaldson SS, Huh W, Maurer H, Michalski J, Qualman S, Ullrich F, Wharam M, Meyer W, Soft-Tissue Sarcoma Committee of the Children's Oncology Group, Arcadia, California, USA: Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group. Pediatr Blood Cancer; 2008 Jul;51(1):17-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The 54 males and 37 females were <1-19 years at diagnosis.
  • Primary sites were nasopharynx-nasal cavity, middle ear/mastoid and parapharyngeal area ("better" sites, 55%), paranasal sinus and infratemporal-pterygopalatine area ("worse" sites, 42%), and other (3%).
  • Major metastatic sites at diagnosis were lung (63%), bone marrow (33%), and bone (27%).
  • Treatment included vincristine, actinomycin D, and cyclophosphamide (VAC) chemotherapy and radiotherapy to the primary tumor and up to five metastatic sites/tissues.
  • Sixty patients had progressive disease (N = 49) or death as a first event (N = 11); another developed myelodysplastic syndrome and died.
  • Factors indicating likelihood of 10-year FFS included tumor arising in "better" versus "worse" sites (FFS 46% vs. 18%, P = 0.02) and embryonal versus other histology (FFS 37% vs. 19%, P = 0.06).
  • CONCLUSIONS: Cure was possible for some patients with metastatic cranial parameningeal sarcoma.
  • Patients with the best outlook had embryonal RMS located in the nasopharynx/nasal cavity, middle ear/mastoid, or parapharyngeal region.
  • Distant metastases were the most frequent type of recurrence, indicating that more effective systemic agents are needed to eliminate residual disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18266224.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-98543; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA-72989; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA-29511
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


41. Xie FY, Peng M, Hu WH, Han F, Wang X, Xu HM: [Prophylactic irradiation of cervical lymph nodes for Stage-N0 nasopharyngeal carcinoma]. Chin J Cancer; 2010 Jan;29(1):106-10
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prophylactic irradiation of cervical lymph nodes for Stage-N0 nasopharyngeal carcinoma].
  • Before treatment, each patient underwent CT or MRI.
  • Doses applied were 60-80 Gy to the nasopharynx and 46-64 Gy to the neck without lymphadenopathy.
  • Consecutive radiotherapy was performed employing conventional fractionation of 2 Gy/fraction, once a day, for a total of five fractions per week.
  • Chemotherapy was administered to 60 patients.
  • [MeSH-major] Lymph Nodes / pathology. Lymphatic Irradiation. Lymphatic Metastasis / prevention & control. Nasopharyngeal Neoplasms / radiotherapy. Radiotherapy, High-Energy / methods
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nasopharynx / radiation effects. Neck / radiation effects. Neoplasm Recurrence, Local. Neoplasm Staging. Particle Accelerators. Proportional Hazards Models. Radiotherapy Dosage. Retrospective Studies. Sex Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038321.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Noël G, Dessard-Diana B, Vignot S, Mazeron JJ: [Treatment of nasopharyngeal cancer: literature review]. Cancer Radiother; 2002 Apr;6(2):59-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of nasopharyngeal cancer: literature review].
  • [Transliterated title] Les traitements des cancers du nasopharynx: revue de la littérature.
  • The conventional radiotherapy and the associated treatments improved the prognostic of nasopharyngeal cancer.
  • A better selection of the patients who must have a more aggressive treatment also probably contributed to this improvement.
  • The patients with a locally advanced tumor, with or not an invasion of the base of the skull and/or neurological symptoms, must have an aggressive locally treatment.
  • This probably includes the increase in dose delivered to the tumor via a more conformational radiotherapy, a brachytherapy, radiotherapy in stereotaxic conditions or other techniques.
  • Dose within the tumor must be at least 70 Gy and the prophylactic nodal dose, at least 50 Gy.
  • Association with chemotherapy allowed, on the other hand, an improvement of the prognostic locally advanced cancers.
  • Neoadjuvant or adjuvant chemotherapy was largely used to attempt to limit the risks of systemic dissemination, but an improvement of results was not clearly demonstrated.
  • Salvage treatments are, however, disappointing for when distant relapse occurs which suggests a difference in chemosensitivity between primary tumor and metastasis.
  • [MeSH-major] Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12035485.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 186
  •  go-up   go-down


43. He XY, Hu CS, Ying HM, Wu YR, Zhu GP, Liu TF: Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol; 2010 May;267(5):773-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma.
  • The aim of this study was to evaluate the efficacy and the toxicity of paclitaxel and cisplatin in patients in concurrent radiotherapy for locally advanced nasopharyngeal carcinoma, and to see whether such a regime would be better tolerated than high dose cisplatin plus fluoracil in Chinese patients.
  • Thirty-one patients with locally advanced nasopharyngeal carcinoma were enrolled.
  • Patients were scheduled to receive two courses of concomitant chemotherapy, starting on day 1 and then day 28 during radiotherapy (70-76 Gy in 35-38 fractions in 7-7.5 weeks).
  • Chemotherapy was given by intravenous infusion, paclitaxel 120 mg/m(2) in 3 h, cisplatin 75 mg/m(2) (25 mg/m(2) days 1-3).
  • Adjuvant therapy was paclitaxel 135 mg/m(2) in 3 h, cisplatin 75 mg/m(2) (25 mg/m(2) days 1-3) on weeks 3, 6, 9 after radiotherapy.
  • All patients completed radiotherapy, but for concomitant chemoradiotherapy, 20 of the 31 patients completed the 2 cycles of chemotherapy, while the other 11 could only receive 1 cycle due to various reasons.
  • The median follow-up was 40 months, 2 patients developed locoregional recurrences, one of whom in the cervical lymph nodes, the other in the nasopharynx.
  • The 3-year overall survival rate was 83.9% and the distant metastasis rate at 3 years was 13.6%.
  • In conclusion, paclitaxel with cisplatin as concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma is feasible, safe, and might improve regional control and survival rates in Chinese patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy Dosage. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 2006 Oct;36(10):620-5 [16905756.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1045-53 [15752883.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2643-53 [15226332.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1040-6 [19117692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S112-4 [17848275.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6966-75 [16192584.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4800-5 [17947728.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):1038-42 [16889823.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1107-16 [15752890.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1224-9 [17675395.001]
  • [Cites] Strahlenther Onkol. 2006 Feb;182(2):63-71 [16447012.001]
  • [Cites] Head Neck. 2008 Feb;30(2):235-41 [17657790.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2038-44 [11956263.001]
  • [Cites] Ann Acad Med Singapore. 2008 May;37(5):377-82 [18536823.001]
  • [Cites] Laryngoscope. 2008 Aug;118(8):1357-61 [18528311.001]
  • [Cites] Head Neck. 2004 Feb;26(2):118-26 [14762880.001]
  • [Cites] J Surg Oncol. 2008 Jul 1;98(1):34-41 [18449912.001]
  • [Cites] Med Oncol. 2005;22(3):269-79 [16110138.001]
  • [Cites] Cancer Invest. 2005;23(2):123-8 [15813504.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):672-9 [15936544.001]
  • [Cites] Med Dosim. 2007 Winter;32(4):263-70 [17980826.001]
  • [Cites] J Egypt Natl Canc Inst. 2006 Dec;18(4):348-56 [18301458.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3582-9 [18559875.001]
  • [Cites] Ai Zheng. 2007 Apr;26(4):394-7 [17430659.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):161-8 [16542792.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1285-91 [18505067.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):29-35 [17889386.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] Ai Zheng. 2005 Oct;24(10):1165-72 [16219127.001]
  • (PMID = 19820959.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


44. Lin JC, Liang WM, Jan JS, Jiang RS, Lin AC: Another way to estimate outcome of advanced nasopharyngeal carcinoma--is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys; 2004 Sep 1;60(1):156-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Another way to estimate outcome of advanced nasopharyngeal carcinoma--is concurrent chemoradiotherapy adequate?
  • PURPOSE: To evaluate a simple risk grouping system and determine whether concurrent chemoradiotherapy (CCRT) is adequate for patients with advanced nasopharyngeal carcinoma (NPC).
  • High-risk patients met at least one of the following criteria:.
  • Survival analyses-including nasopharynx disease free (TS), neck disease free (NS), distant metastasis disease free (MS), overall survival (OS), and progression-free (PFS) survival curves-were compared between these three different classifications.
  • Adding neoadjuvant and/or adjuvant chemotherapy would be a reasonable approach for high-risk patients.
  • Our risk grouping criteria are a simple and useful guide that will have important implications in the design of future therapeutic trials.
  • [MeSH-major] Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk. Treatment Failure


45. Bagatzounis A, Erakleous E, Michaelides I: Epidural metastasis in nasopharyngeal carcinoma. Strahlenther Onkol; 2003 Feb;179(2):123-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidural metastasis in nasopharyngeal carcinoma.
  • BACKGROUND: In nasopharyngeal carcinoma, both, a short metastasis-free interval after primary treatment and the occurrence of epidural metastasis have been associated with poor prognosis.
  • PATIENT: A 26-year-old male with stage T2N3M0 non-keratinizing carcinoma (WHO type 2) of the nasopharynx was treated with induction chemotherapy and radical radiotherapy, 6 months after documentation of a clinical complete remission, the patient experienced metastatic disease to the C7-D1 vertebral bodies associated with an epidural soft tissue mass.
  • Since no further metastatic lesions were detectable, the patient was treated with radiotherapy alone (3 960 cGy/22 fractions).
  • RESULTS: Treatment resulted in compete resolution of neurological and radiological signs of the disease and the patient continues to be disease-free, 32 months after salvage treatment.
  • In a literature search, we identified 54 reported cases with long-term survival after treatment for metastatic nasopharyngeal cancer.
  • The vast majority of them had primary tumors with undifferentiated histology and was treated with combination chemotherapy.
  • In 25 of them, radiotherapy was given as consolidation therapy (in 19 cases for bone and in six cases for mediastinal lymph node metastases).
  • CONCLUSIONS: Epidural metastatic disease from a nasopharyngeal carcinoma is highly sensitive to moderate doses of fractionated radiotherapy.
  • MR imaging is essential for the detection of relevant soft tissue disease extensions within the epidural space and proper selection of the radiation target volume in vertebral metastases.
  • In patients with nasopharyngeal carcinoma, the occurrence of a solitary epidural metastasis after a short metastasis-free interval is not incompatible with long-term survival.
  • [MeSH-major] Carcinoma / secondary. Epidural Neoplasms / secondary. Nasopharyngeal Neoplasms
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cervical Vertebrae. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Dose Fractionation. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Leucovorin / therapeutic use. Magnetic Resonance Imaging. Male. Prognosis. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Thoracic Vertebrae. Time Factors

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12590324.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


46. Nasr Ben Ammar C, Kochbati L, Lejri N, Chaouache K, Frikha H, Besbes M, Touati S, Ben Abdallah M, Maalej M: [Prognostic value of parapharyngeal extension in nasopharyngeal carcinoma]. Tunis Med; 2009 Dec;87(12):814-7
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic value of parapharyngeal extension in nasopharyngeal carcinoma].
  • [Transliterated title] Valeur pronostique de l'extension parapharyngéee dans les carcinomes nasopharyngés.
  • AIM: This study evaluated the prognostic value of the Para pharyngeal space involvement in nasopharyngeal carcinoma T 2 disease (UICC 1997 classification).
  • METHODS: From January 1997 and December2001; 32 patients with nasopharyngeal carcinoma were examined by CT scan and according to the 1997 International Union Against Cancer (UICC) staging system, 15 had stage T2a M0 (G1) and 17 T2bM0(G2).
  • All patients were pathologically confirmed by biopsy from the nasopharynx as having UCNT in 100% (G1) and 94% (G2).
  • Both neoadjuvant chemotherapy and radiotherapy were performed for advanced N disease and only radiotherapy for NO.
  • The completely clinical remission after chemotherapy was 12.5% (G1) and 53% (G2), partial remission was 25% (G1) and 35% (G2).
  • Distant metastasis rates were 26% (G1) vs 6% (G2) and more likely in the presence of advanced N disease.
  • Five years overall survival was 78% (G1) T2a vs. 55% (G2) T2b.The N disease was correlated to metastasis as overall survival was 66.7% for N3 disease vs 85.7% for N0.
  • CONCLUSION: Parapharyngeal tumor involvement affects local and regional tumor failure.
  • Subclassification of T2 disease into T2a/T2b should have an impact on treatment strategies.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / pathology. Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / pathology. Nasopharynx / pathology
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20209847.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


47. Lu TX, Zhao C, Han F, Huang Y, Deng XW, Lu LX, Zeng ZF, Huang SM, Lin CG, Cui NJ: [Intensity modulated radiation therapy for 49 patients with recurrent nasopharyngeal carcinoma]. Zhonghua Zhong Liu Za Zhi; 2003 Jul;25(4):386-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intensity modulated radiation therapy for 49 patients with recurrent nasopharyngeal carcinoma].
  • OBJECTIVE: To evaluate the feasibility, toxicity and tumor control of intensity modulated radiation therapy (IMRT) for recurrent nasopharyngeal carcinoma.
  • METHODS: Fourty-nine patients (Karnofsky performance status (KPS) >or= 80) with local-regional recurrence in the nasopharynx were treated with full course IMRT.
  • Three patients with cervical lymph node metastasis (N1 2 and N3 1) were further supplemented with 5 to 6 courses of chemotherapy (Cisplatin + 5-Fu) after IMRT.
  • RESULTS: The results of treatment plan showed that the mean dose of covering gross tumor volume (GTV) (D(95)) in the nasopharynx was 68.09 Gy and the mean volume of GTV (V(95)) receiving the 95% dose was 98.46%.
  • The mean dose of GTV, clinical target volume CTV1 and CTV2 in the targets were 71.40 Gy, 63.63 Gy and 59.81 Gy.
  • The median follow-up time was 9 months (range 3 to 16 months).
  • The local-regional progression-free survival was 100% with local-regional residual disease in 3 (6.1%) cases but was complicated with nasopharyngeal mucosa necrosis in 14 (28.6%) cases after IMRT.
  • CONCLUSION: Intensity modulated radiation therapy, as a re-treatment option for recurrent nasopharyngeal carcinoma, is able to improve the tumor target coverage and spare the adjacent critical structures.
  • As high dose IMRT can result in radio-necrosis of nasopharyngeal mucosa, the prescription dose of GTV should be suitably decreased to 60 - 65 Gy.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Radiation Injuries / pathology. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12921573.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


48. Beckmann G, Flentje M: [Present status of treatment in nasopharyngeal carcinoma?]. Strahlenther Onkol; 2003 May;179(5):283-91
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Present status of treatment in nasopharyngeal carcinoma?].
  • [Transliterated title] Wo stehen wir bei der Behandlung des Nasopharynxkarzinoms?
  • AIM: Review of the evolution of combined treatment strategies in nasopharyngeal carcinoma.
  • RESULTS: Radiotherapy is accepted standard for treatment of nasopharyngeal cancer.
  • Nevertheless, there is no uniform opinion with regard to doses, fractionation, technique or use of systemic chemotherapy.
  • It is hardly possible to compare the results of recent and historical trials because of different staging systems and because nasopharyngeal cancer occurring in the Oceano-Asian region are biologically different to those in Western countries.
  • Conclusions drawn from former, mostly retrospective analyses are not applicable to newer standards regarding the developments in diagnostics and therapy.
  • Presently simultaneous chemoradiotherapy is standard for lymph node positive nasopharyngeal cancer.
  • CONCLUSIONS: It will be necessary to treat patients with different histologic subtypes with an uniform treatment schedule to define the place of combined modality treatment.
  • This will probably be the only way to develop treatment concepts for distinct stages and biological entities.
  • [MeSH-major] Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Humans. Lymphatic Metastasis. Multicenter Studies as Topic. Nasopharynx / pathology. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Prospective Studies. Radiotherapy / adverse effects. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Remission Induction. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12740654.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 51
  •  go-up   go-down


49. Wang CP, Chang YL, Chen CT, Yang TH, Lou PJ: Photodynamic therapy with topical 5-aminolevulinic acid as a post-operative adjuvant therapy for an incompletely resected primary nasopharyngeal papillary adenocarcinoma: a case report. Lasers Surg Med; 2006 Jun;38(5):435-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with topical 5-aminolevulinic acid as a post-operative adjuvant therapy for an incompletely resected primary nasopharyngeal papillary adenocarcinoma: a case report.
  • BACKGROUND AND OBJECTIVES: Surgical excision of primary nasopharyngeal papillary adenocarcinoma is sometimes incomplete with remaining microscopic disease.
  • STUDY DESIGN/MATERIALS AND METHODS: Photodynamic therapy (PDT) was used as a post-operative adjuvant therapy for an incompletely resected primary nasopharyngeal papillary adenocarcinoma.
  • A special form of 20% topical 5-aminolevulinic acid (5-ALA), which was originally a liquid form and became a gel form after applied on the nasopharynx, was used as the photosensitizer.
  • RESULTS: No significant acute side effect was noted and the nasopharyngeal wound healed rapidly.
  • The patient is alive without locoregional recurrence or distant metastasis for 5 years.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Aminolevulinic Acid / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Administration, Topical. Adult. Combined Modality Therapy. Female. Humans. Postoperative Care. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16470845.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


50. Xie FY, Huang HY, Hu JZ: [Observation on effect of radiotherapy and antike capsule combination therapy in treating nasopharyngeal cancer patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2001 Dec;21(12):888-90
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Observation on effect of radiotherapy and antike capsule combination therapy in treating nasopharyngeal cancer patients].
  • OBJECTIVE: To compare the effect of radiotherapy (RT) combined with Antike capsule (AC) and RT alone in treating nasopharyngeal cancer (NPC) patients.
  • METHODS: Eighty-nine patients with pathologically confirmed NPC (stage II-IV) were randomly divided into two groups: group A (46 cases) were treated with RT, receiving 65-70 Gy/6.5-7 weeks to nasopharynx region and the same dosage to neck region, and AC was given in combination.
  • The total dosis of RT for complete remission (CR) of primary nasopharyngeal tumor and neck lymph nodes, the CR rate and the changes of peripheral NK cell, T lymphocyte subsets in the two groups were compared.
  • RESULTS: The total dosis of RT for CR in group A and B were 41.6 +/- 8.9 Gy vs 50.7 +/- 9.2 Gy for primary nasopharyngeal tumor, P < 0.05 and 47.4 +/- 10.3 Gy vs 56.2 +/- 9.7 Gy for neck lymph nodes, P < 0.05.
  • The CR rate of primary nasopharyngeal tumor in group A and B were 93.5% and 88.4% respectively, P < 0.05.
  • The activity of NK cell as well as T3, T4 in peripheral blood increased significantly in the group A after treatment, P < 0.05, while in group B, T3, T4 lowered significantly, P < 0.05.
  • CONCLUSION: RT combined with AC could be helpful in elevating and promoting the remission rate of primary tumor and neck lymph nodes, and AC has some effects in improving the immune function and general condition in NPC patients during RT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12575586.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Capsules; 0 / Cobalt Radioisotopes; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


51. Liu T, Ding Y, Xie W, Li Z, Bai X, Li X, Fang W, Ren C, Wang S, Hoffman RM, Yao K: An imageable metastatic treatment model of nasopharyngeal carcinoma. Clin Cancer Res; 2007 Jul 1;13(13):3960-7
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An imageable metastatic treatment model of nasopharyngeal carcinoma.
  • PURPOSE: Nasopharyngeal carcinoma is highly prevalent in southern China and is often resistant to current treatment options.
  • EXPERIMENTAL DESIGN: Clinically relevant mouse models are necessary for further understanding and drug discovery in this disease.
  • Two nasopharyngeal carcinoma cell lines, stably expressing green fluorescent protein (GFP), 5-8F-GFP and 6-10B-GFP, were established.
  • The cells were orthotopically injected into the nasopharynx or ectopically into the subcutis of nude mice.
  • Whole-body fluorescence imaging was used to monitor the growth of the primary tumor as well as angiogenesis and metastasis.
  • RESULTS: The metastatic behavior of 5-8F and 6-10B were distinct in the orthotopic model.
  • Orthotopic implantation of highly metastatic 5-8F cells resulted in brain invasion, cervical lymph node metastases, and pulmonary metastases similar to what is often observed in patients.
  • Cell line 6-10B was less metastatic, which occasionally resulted in pulmonary metastasis.
  • Neither 5-8F nor 6-10B were metastatic in the s.c. site.
  • These results indicated that, in addition to the cancer cell type, the host microenvironment was critical for metastasis to occur consistent with the "seed-and-soil" hypothesis.
  • CONCLUSIONS: The imageable orthotopic model should play a critical role in elucidating the mechanisms involved in the growth, progression, metastasis, and angiogenesis of nasopharyngeal carcinoma and for evaluation of novel compounds with potential efficacy.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / therapy. Disease Models, Animal. Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Green Fluorescent Proteins / metabolism. Humans. Mice. Mice, Nude. Microscopy, Fluorescence. Models, Anatomic. Neoplasm Metastasis. Neoplasm Transplantation. Neovascularization, Pathologic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606730.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


52. Seriakov AP, Kopychev IuE, Gorbunov VA, Zav'ialov MS, Kubyshkin SI, Smolin AV, Sukirko VA: [Combined (chemo-radiation) treatment of patients with nasopharyngeal cancer]. Voen Med Zh; 2005 Nov;326(11):38-43, 111
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined (chemo-radiation) treatment of patients with nasopharyngeal cancer].
  • The efficacy of parallel and successive chemoradial treatment of patients with nasopharynx carcinoma was investigated in the radiological center of Burdenko MMCH.
  • 71% of the patients had the 3rd and the 4th stages of the tumor process; 29% had the 1st and the 2nd stages; 68,6% had the metastatic nodal involvement of regional zones.
  • The radial therapy of the locoregional zone was administered by means of the splitting course using the classic method of fractionating a dose up to the total optimal dose of 64-70 Gr.
  • Due to the treatment the 5-year survival rate increased from 41,2% to 78,5% (P < 0,001).
  • With the metastatic nodal involvement of regional zones that rate reduced from 83,3% to 72,8% (P > 0,05) in the main group and from 63,8% to 31,9% (P < 0,001) in the control group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Radiation Dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404906.001).
  • [ISSN] 0026-9050
  • [Journal-full-title] Voenno-medit︠s︡inskiĭ zhurnal
  • [ISO-abbreviation] Voen Med Zh
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


53. Maillard S, Merol JC, Chays A, Nguyen TD: [In reference to the article: "Neck dissection following chemoradiation for node positive head and neck carcinomas" by Thariat et al. Cancer Radiother 2009;13:758-770]. Cancer Radiother; 2010 Jun;14(3):222; author reply 222-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] A propos de l'article : << Place du curage ganglionnaire après chimioradiothérapie dans les carcinomes des voies aérodigestives supérieures avec atteinte ganglionnaire initiale (nasopharynx exclu) >> par Thariat et al. Cancer Radiother 2009;13:758-770.
  • [MeSH-minor] Alphapapillomavirus. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Clinical Trials as Topic. Combined Modality Therapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Neoadjuvant Therapy. Neoplasm Staging. Papillomavirus Infections. Radiotherapy, Adjuvant. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Radiother. 2009 Dec;13(8):758-70 [19692283.001]
  • (PMID = 20189432.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comment; Letter
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement